2017 American Transplant Congress
Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants.
Aim: Characteristics of de novo donor-specific HLA antibodies (dnDSA) that are associated with C4d positive antibody-mediated rejection (C4d+ AMR) in kidney transplants have not been…2017 American Transplant Congress
HLA Alloimmunization According to the Different Immunization Events and Consequences on Access to Kidney Transplantation.
Patients awaiting solid organ transplantation may develop anti-HLA antibodies after sensitization events such as transfusions, pregnancies or previous transplantations. The aim of our work was…2017 American Transplant Congress
Influence of Donor-Specific Antibodies on Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Llobregat Catalunya, Spain; 2Novartis Pharma AG, Basel, Switzerland
Purpose: The development of donor-specific antibody (DSA) is a known risk factor for poor graft outcomes after kidney transplantation (KTx). Previous analysis of the ELEVATE…2017 American Transplant Congress
Comparison Between IgG, C1q and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
Introduction. Donor specific antibodies (DSA) are associated with an increased risk of chronic antibody mediated rejection (CAMR). DSA characterization by single antigen bead (SAB) assays…2017 American Transplant Congress
IVIG + Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly Hla Sensitized (HS) Awaiting Deceased Donor Kidney Transplantation.
Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
Background: HS patients are at risk for development of donor specific antibodies (DSA) and the persistence of DSA is associated with poor graft outcomes. Rituximab,…2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…2017 American Transplant Congress
Circulating Donor-Specific Anti-HLA Antibodies Accelerate the Progression of Interstitial Fibrosis in Kidney Allografts.
Paris Translational Research Center for Organ Transplantation, Paris, France
Interstitial fibrosis represents a major cause of kidney allograft failure. Addressing the causes of accelerated ageing of kidney allografts represents an important challenge to improve…2017 American Transplant Congress
C3d-Binding Anti-DQ DSA Is Associated with a High Risk for Late ABMR and Graft Failure in Stable Kidney Transplant Recipients.
Introduction:Donor specific anti-HLA antibodies (DSA) are a major cause of antibody-mediated rejection (ABMR) and poor graft outcome in kidney transplant recipients (KTR). Critical issue is…2017 American Transplant Congress
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).
Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…2017 American Transplant Congress
Refinement of an Old Faithful: A Standardized Flow Cytometry Approach to Measure Donor-Recipient Alloreactivity (a Pilot Study).
Purpose: Donor-specific antibody (DSA) and antibody (Ab)-mediated rejection are challenges in long-term outcomes and limit re-transplantation. Sensitizing events such as homografts in surgical procedures, assist…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 47
- Next Page »